Boceprevir triple therapy of chronic HCV genotype 1 (G1) infection in previously untreated patients: Efficacy, predictability of virologic response and safety in German real-life
P Buggisch, H Löhr, G Teuber, H Steffens, M Kraus, P Geyer, B Weber, T Witthöft, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer · Zeitschrift für Gastroenterologie · 2015 · Heft 12
Bibliografische Angaben
Zusammenfassung
Background: Since 2011, triple therapy with the HCV protease inhibitor boceprevir (BOC) is widely used as standard of care for patients (pts) with chronic HCV G1 infection. Here we report the German experience obtained from the NOVUS observational study with respect to efficacy, safety and predictability of virologic outcome in previously untreated pts undergoing BOC triple therapy in real-life. Methods: From April 2012 until January 2014, 536 pts with G1 infection were recruited in the ongoing NOVUS study by 97 practices and hospitals in Germany. Pts were treated with pegylated interferons (PegIFN) and ribaviri…
